Skip to main content

Table 1 Outcomes for efficacy, net-benefit and safety up to 30 days, 180 days and to maximal follow-up (mean 25 months)

From: Impact of thrombus aspiration during ST-Elevation Myocardial Infarction: a six month composite endpoint and risk of stroke analyses of the TASTE trial

Outcome Thrombus aspiration N = 3621 PCI alone N = 3623 Hazard ratio (95 % CI) P-value
Efficacy up to 180 days     
Cardiovascular (CV) death 125 (3.5 %) 133 (3.7 %) 0.94 (0.74-1.20) 0.62
All cause death 145 (4.0 %) 156 (4.3 %) 0.93 (0.74-1.17) 0.52
Rehospitalisation for new myocardial infarction (Rehosp-MI) 63 (1.7 %) 70 (1.9 %) 0.90 (0.64-1.26) 0.53
Definite stent thrombosis (ST) 20 (0.6 %) 26 (0.7 %) 0.77 (0.42-1.37) 0.37
Target vessel revascularization (TVR) 130 (3.6 %) 144 (4.0 %) 0.90 (0.71-1.14) 0.38
Cardiogenic chock or new hospitalisation with heart failure (HF) 176 (4.9 %) 186 (5.1 %) 0.95 (0.77-1.16) 0.59
CV death, cardiogenic shock, Rehosp-MI or new heart failure (HF)a 316 (8.7 %) 338 (9.3 %) 0.93 (0.80-1.09) 0.36
Cardiovascular death, cardiogenic shock, Rehosp-MI, new HF, definite ST or TVR 409 (11.3 %) 448 (12.4 %) 0.91 (0.79-1.04) 0.15
Efficacy during follow-up (median 25 months)     
Cardiovascular death 215 (5.9 %) 229 (6.3 %) 0.94 (0.78 - 1.13) 0.51
Cardiovascular death, cardiogenic shock, Rehosp-MI or new HFa 483 (13.3 %) 521 (14.4 %) 0.92 (0.82-1.05) 0.21
Cardiovascular death, cardiogenic shock, Rehosp-MI, new HF, definite ST or TVR 615 (17.0 %) 678 (18.7 %) 0.90 (0.81-1.00) 0.058
Safety     
Stroke up to 30 days 24 (0.7 %) 27 (0.7 %) 0.89 (0.51-1.54) 0.68
Stroke up to 180 days 42 (1.2 %) 45 (1.2 %) 0.93 (0.61-1.42) 0.75
Stroke until follow up (median 25 months) 89 (2.5 %) 89 (2.5 %) 1.00 (0.75-1.34) 0.99
Net-benefit up to 180 days     
Cardiovascular death, cardiogenic shock, Rehosp-MI, new HF, or strokeb 343 (9.5 %) 371 (10.2 %) 0.92 (079-1.07) 0.27
Cardiovascular death, cardiogenic shock, Rehosp-MI, new HF, stroke, definite ST or TVRc 436 (12.0 %) 479 (13.2 %) 0.90 (0.79-1.03) 0.12
Net-benefit during follow-up (median 25 months)     
Cardiovascular death, cardiogenic shock, Rehosp-MI, new HF, or strokeb 545 (15.1 %) 582 (16.1 %) 0.93 (0.83-1.05) 0.24
Cardiovascular death, cardiogenic shock, Rehosp-MI, new HF, stroke, definite ST or TVRc 677 (18.7 %) 736 (20.3 %) 0.91 (0.82-1.01) 0.08
  1. aDenotes the primary quadruple composite endpoint within 180 days and also the same quadruple endpoint, during follow up (median 25 months)
  2. bDenotes the net-benefit composite endpoint up to 180 days and during follow-up
  3. cDenotes the extended net-benefit composite endpoint within 180 days and during follow-up